Search
Levacetylmethadol
go.drugbank.com/drugs/DB01227ApprovedWithdrawnLevacetylmethadol is a narcotic analgesic with a long onset and duration of action. It is used mainly in the treatment of narcotic dependence. Levacetylmethadol was withdrawn from use in the European Union due to its high risk of QT inte...
Zanidatamab
go.drugbank.com/drugs/DB15471ApprovedInvestigationalZanidatamab is a bispecific antibody that binds two non-overlapping sites of HER2 (ERBB2). It has been investigated for the treatment of HER2-positive solid tumors, including gastroesophageal, colorectal, and biliary tract cancers. In No...
Flotufolastat F-18
go.drugbank.com/drugs/DB17851ApprovedInvestigationalFlotufolastat F-18 (18F-rhPSMA-7.3) is an 18F-labeled ligand that targets the prostate-specific membrane antigen (PSMA). In patients with recurrent prostate cancer that require localized treatment, the use of 18F-labeled ligands for posi...
Tyramine
go.drugbank.com/drugs/DB08841InvestigationalNutraceuticalTyramine acts by inducing the release of catecholamine.
NLX-P101
go.drugbank.com/drugs/DB05924ExperimentalNLX-P101, gene therapy is developed by Neurologix to treat Parkinson’s disease.
AG0301-COVID19
go.drugbank.com/drugs/DB15856InvestigationalAG0301-COVID19 is a vaccine candidate developed by AnGes Inc. and Osaka University.
Lisocabtagene maraleucel
go.drugbank.com/drugs/DB16582ApprovedInvestigationalLisocabtagene maraleucel is a chimeric antigen receptor (CAR) T-cell therapy, similar to brexucabtagene autoleucel and axicabtagene ciloleucel. Lisocabtagene maraleucel is a genetically modified autologous T-cell therapy that targets CD1...
N-[(2S,4S,6R)-2-(dihydroxymethyl)-4-hydroxy-3,3-dimethyl-7-oxo-4lambda~4~-thia-1-azabicyclo[3.2.0]hept-6-yl]-2-phenylacetamide
go.drugbank.com/drugs/DB08559ExperimentalThese are organic compounds containing the penicillin core structure, which is structurally characterized by a penam ring bearing two methyl groups at position 2, and an amide group at position 6 [starting